Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion studyUdai Banerji, Philippe Aftimos, Carla M.L. van Herpen et al.|The Lancet Oncology|2019Cited by 564
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancerAditya Bardia, Sara A. Hurvitz, Sara M. Tolaney et al.|Annals of Oncology|2021Cited by 294
Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid TumorsMatthew D. Hellmann, Toshihiko Doi, F. Stephen Hodi et al.|Clinical Cancer Research|2021Cited by 111
Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cellsTaronish D. Dubash, Shyamala Maheswaran, Aditya Bardia et al.|Breast Cancer Research and Treatment|2023Cited by 6